Glenmark secures USFDA approval for generic Desoximetasone ointment
Glenmark will commence the shipping of the product immediately.
New Delhi, September 23, 2013: Glenmark Pharmaceuticals has received the final approval from the US health regulator for its generic Desoximetasone ointment. The company aims to begin the shipping of the product immediately.
"Glenmark Generics Inc USA, the subsidiary of Glenmark Generics Ltd has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Desoximetasone Ointment USP, 0.25 per cent," the company said in a statement.
The company plans to begin shipping the product on an immediate basis. As per the IMS Health data, Desoximetasone Ointment registered sales of US$ 40 million annually. The company currently has 89 products authorised for distribution in the American market and another 54 ANDSs are pending approval with the USFDA.